Author: Andrei Bilog M.Sc., CAPM

Pancreatic cancer — particularly pancreatic ductal adenocarcinoma (PDAC) — remains one of oncology’s most daunting challenges. With a five-year survival rate lingering in the single digits, innovative approaches in molecular oncology are desperately needed. In late 2025, renowned cancer researcher Mariano Barbacid, PhD, and his team at Spain’s Centro Nacional de Investigaciones Oncológicas (CNIO) published compelling preclinical evidence that a targeted combination therapy can eliminate PDAC tumors in mice with no observed recurrence — an outcome that could reshape therapeutic strategies in this field. (CNIO)

Mariano Barbacid, PhD, is a Spanish molecular oncologist best known for his seminal discovery of the first human oncogene (HRAS) in 1982, laying crucial groundwork for molecular cancer biology. (AACR) After decades in cancer research — including leadership roles in both the U.S. and Europe — Barbacid now heads the Experimental Oncology Group at CNIO, focusing on KRAS-driven tumors, which are implicated in about 90 % of pancreatic cancers. (CNIO)

In a December 2025 paper published in Proceedings of the National Academy of Sciences, Barbacid and co-authors reported that a triple targeted therapy achieves complete regression of orthotopic PDAC tumors in mice and prevents drug resistance, a major barrier in current treatment regimens. (PubMed)

The therapy combines:

With this configuration, the team achieved durable tumor regression for over 200 days in vivo without signs of relapse or severe toxicity. (PubMed)

PDAC’s notorious resistance to therapy stems from the cancer’s ability to adapt via redundant survival pathways. Standard chemotherapy often slows, but does not halt, disease progression. By simultaneously inhibiting multiple survival signals downstream of KRAS, Barbacid’s approach addresses adaptive resistance — a major cause of therapeutic failure in PDAC. (PubMed)

These results — while preclinical — provide a scientific foundation for combination strategies and help inform rational drug design and trial planning. The absence of resistance in animal models suggests that future clinical applications could break the cycle of short-lived treatment responses. (CNIO)

For students and professionals, this work underscores the importance of integrating molecular biology, pharmacology, and translational medicine. Understanding signaling networks like KRAS, EGFR, and STAT3 — and how they can be jointly targeted — exemplifies next-generation therapeutic development in biopharma. (Mariano Barbacid)

While promising, Barbacid’s therapy has not yet entered human clinical trials. The researchers themselves emphasize that optimizing and safely translating this combination for patients will take time and careful study. (CNIO)

Nevertheless, the proof-of-concept established here accelerates ongoing efforts to target “undruggable” oncogenes like KRAS and opens avenues for innovative, multi-agent regimens that could, in the coming decade, redefine how the deadliest cancers are treated.

Disclaimer: This article was assisted by AI-based language tools (ChatGPT, OpenAI) for drafting and organization. All content was reviewed by the author, and all claims are supported by peer-reviewed sources.

Barbacid, M., Liaki, V., Barrambana, S., & Guerra, C. (2025). A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proceedings of the National Academy of Sciences. (PubMed)

Guerra, C., Pérez-Mancera, P. A., Barbacid, M., & Tuveson, D. A. (2012). What we have learned about pancreatic cancer from mouse models. Gastroenterology, 142, 1079–1092. (PubMed)

Barbacid, M. (1982). A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder-carcinoma oncogene. Nature, 300(5888), 149–152. (Wikipedia)

SD36. (2026). Wikipedia. (Wikipedia)

Centro Nacional de Investigaciones Oncológicas (CNIO). (2026). CNIO news: Pancreatic tumors eliminated in mice. (CNIO)